Pulmonx Corporation reports developments as a medical technology company focused on minimally invasive treatments for severe emphysema and chronic obstructive pulmonary disease. Its commercial platform includes the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform and StratX Lung Analysis Reports, which are designed to assess and treat symptomatic severe emphysema/COPD patients. The Zephyr Valve received FDA premarket approval after breakthrough device designation and is commercially available in more than 25 countries.
Recurring Pulmonx news covers quarterly and annual financial results, U.S. and international revenue trends, gross margin, commercial execution, clinical program activity, debt refinancing, cost initiatives, inducement equity awards and governance or leadership changes.
Pulmonx Corporation has announced the pricing of its upsized initial public offering (IPO) of 10,000,000 shares at $19.00 each, totaling gross proceeds of $190 million. The offering includes a 30-day option for underwriters to purchase an additional 1,500,000 shares. Trading on the Nasdaq under the symbol 'LUNG' will commence on October 1, 2020, with the expected close on October 5, 2020. BofA Securities and Morgan Stanley lead the offering, which was declared effective by the SEC on the same day.